Ozempic Price Cut and Oprah's Weight Loss Journey Spark Nationwide Conversation About GLP-1 Medications cover art

Ozempic Price Cut and Oprah's Weight Loss Journey Spark Nationwide Conversation About GLP-1 Medications

Ozempic Price Cut and Oprah's Weight Loss Journey Spark Nationwide Conversation About GLP-1 Medications

Listen for free

View show details

About this listen

 Ozempic has dominated headlines again this week as Novo Nordisk announced a major price cut, making the diabetes drug available for 499 dollars per month to eligible cash-paying patients in the United States for the first time through their NovoCare pharmacy program and in partnership with telehealth provider GoodRx. This move follows similar pricing for Wegovy, a sister drug prescribed primarily for weight loss, and responds to mounting public and political pressure to reduce drug costs in the US, which have traditionally far outpaced those in other countries. The rapid expansion of access has sparked renewed debate on the cultural and medical impact of GLP-1 drugs, with product demand and public interest remaining extremely high.

In the same news cycle, Oprah Winfrey once again became a focal point of national conversation about weight loss and Ozempic. Recent photos posted from her vacation in Italy, where she was seen truffle hunting, have drawn widespread notice for her noticeably slimmer figure. While the food adventure was part of the public narrative, much of the commentary was focused on Oprah’s dramatic transformation. Earlier this year on her podcast, Oprah spoke candidly about her experience with so-called GLP-1 medications. She shared that after starting on the medicine, which functions by suppressing appetite, she began to understand how differently people can experience hunger. For years, she admits, she attributed thinness to willpower, assuming that some people simply had better self-control around food. The drug shifted her perspective, making her realize the powerful biological factors at play and how GLP-1 drugs can create a level playing field for those with obesity, a condition the talk show icon now insists is a disease of the brain, not a failure of character.

Oprah's public acknowledgment of using weight loss medication was itself notable, given the intense stigma and the climate of secrecy around pharmaceutical weight loss among celebrities. She described feeling "relief," "redemption," and gratitude that she could finally manage chronic weight struggles with a tool that's medically approved. Despite having initially resisted the idea, citing a belief that using drugs was the “easy way out,” Oprah has since changed her position and has called for an end to self-blame and societal shaming. In her words, shame has been replaced by a sense of liberation, both from her own self-judgment and from external criticism. She no longer sees the use of weight loss drugs as something to be hidden or ridiculed.

Medical experts weighing in this week have reiterated that Ozempic and other GLP-1 medicines do produce significant weight loss and improvements in cholesterol and triglyceride levels as long as patients continue taking them. Ziyad Al-Aly, chief of research at the Veterans Affairs St. Louis Healthcare System, emphasizes that the drugs enhance not just weight management but overall metabolic health. However, there are crucial caveats: studies published this week in Diabetes Obesity and Metabolism confirm that stopping GLP-1 medication typically results in regaining as much as two-thirds of the lost weight and a reversal of most health benefits. This so-called rebound effect has caused concern among physicians, who urge patients to understand the drugs are best considered a long-term therapy rather than a short-term fix.

As demand spikes, news of rare but concerning adverse effects, such as potential vision changes, has kept the safety discussion alive, though current expert consensus is that for most people prescribed these medications appropriately, the benefits outweigh the risks. Meanwhile, Novo Nordisk and other drug makers continue racing to expand access through direct pharmacy programs, with Eli Lilly also announcing price reductions and new supply chain solutions for its own competing drug Zepbound.

On social media and in mainstream culture, public acceptance of GLP-1 treatments appears to be moving quickly, especially with high-profile advocates like Winfrey openly discussing their use and encouraging an end to the blame game around obesity. As Oprah underscored in her latest episodes, the real shift is away from stigma and toward a greater understanding of the science of obesity and the power of new medications to address it as a medical condition, not a moral failing.

Thanks for listening, please subscribe, and remember—this episode was brought to you by Quiet Please podcast networks. For more content like this, please go to Quiet Please dot Ai. Come back next week for more.

Some great Deals https://amzn.to/49SJ3Qs

For more check out http://www.quietplease.ai

This content was created in partnership and with the help of Artificial Intelligence AI
No reviews yet
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.